The role of scintigraphy with 123I meta-iodobenzylguanidine in the differential diagnosis of 4 and 4S neuroblastoma stage: description of a clinical case
https://doi.org/10.17650/2311-1267-2016-3-4-91-95
Abstract
The article describes the clinical case and the complexity of the staging of the disease the patient’s first year of life with neuroblastoma (NB) of the neck. Shows diagnostic search aimed at identifying distant metastasis of the tumor. Highlighted perform scintigraphy with 123I metaiodobenzylguanidine to detect distant metastases in patients with NB and correct stratification of patients into risk groups.
About the Authors
T. V. Shamanskaya
Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia;
Russian Federation
1 Samory Mashela St., Moscow, 117997
Russian Federation
1 Samory Mashela St., Moscow, 117997
D. Yu. Kachanov
Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia;
Russian Federation
1 Samory Mashela St., Moscow, 117997
Russian Federation
1 Samory Mashela St., Moscow, 117997
Yu. N. Likar
Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia;
Russian Federation
1 Samory Mashela St., Moscow, 117997
Russian Federation
1 Samory Mashela St., Moscow, 117997
A. P. Shcherbakov
Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia;
Russian Federation
1 Samory Mashela St., Moscow, 117997
Russian Federation
1 Samory Mashela St., Moscow, 117997
S. R. Varfolomeeva
Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia;
Russian Federation
1 Samory Mashela St., Moscow, 117997
Russian Federation
1 Samory Mashela St., Moscow, 117997
References
1. Cheung N.K., Dyer M.A. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer 2013;13(6):397–411.
2. Качанов Д.Ю., Шаманская Т.В., Муфтахова Г.М., Варфоломеева С.Р. Нейробластома 4S стадии. Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2014;13(2):9–19. [Kachanov D.Yu., Shamanskaya T.V., Muftakhova G.M., Varfolomeeva S.R. Stage 4S neuroblastoma. Voprosy gematologii/onkologii i immunopatologii v pediatrii = Pediatric Hematology/Oncology and Immunopathology 2014;13(2):9–19. (In Russ.)].
3. Kushner B.H. Neuroblastoma: A disease requiring a multitude of imaging studies. J Nucl Med 2004;4:1172–88.
4. Rufini V., Shulkin B. The evolution in the use of MIBG in more than 25 years of experimental and clinical applications. Q J Nucl Med Mol Imaging 2008;52(4):341–50.
5. Brisse H.J., McCarville M.B., Granata S. et al. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology 2011;261:243–57.
6. Mueller W.P., Coppenrath E., Pfluger T. Nuclear medicine and multimodality imaging of pediatric neuroblastoma. Pediatr Radiol 2013;43:418–27.
7. Monclair T., Brodeur G.M., Ambros P.F. et al. INRG Task Force. The International Neuroblastoma Risk Group (INRG) staging system: An INRG Task Force report. J Clin Oncol 2009;27:298–303.
8. Shulkin B.L., Shapiro B. Current concepts on the diagnostic use of MIBG in children. J Nucl Med 1998;39:679–88.
9. De Bernardi B., Gerrard M., Boni L. et al. Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. J Clin Oncol 2009;27(7):1034–40.
Review
For citations:
Shamanskaya T.V., Kachanov D.Yu., Likar Yu.N., Shcherbakov A.P., Varfolomeeva S.R. The role of scintigraphy with 123I meta-iodobenzylguanidine in the differential diagnosis of 4 and 4S neuroblastoma stage: description of a clinical case. Russian Journal of Pediatric Hematology and Oncology. 2016;3(4):91-95. (In Russ.) https://doi.org/10.17650/2311-1267-2016-3-4-91-95
Views:
598
Email this article 